2024. Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%). SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s421. DOI:https://doi.org/10.25251/skin.8.supp.421.